TYK2 is a central mediator of core inflammatory pathways in psoriasis – IL-23/IL-17 axis and type I interferon signaling – making it a promising target as inhibition of a single pathway may not fully control disease for every patient.14,18,29 TYK2 is an intracellular enzyme and member of the Janus kinase (JAK) protein family.14-15 However, TYK2 is distinct from JAK1, 2 and 3 as it primarily regulates immune responses, whereas JAK1, 2 and 3 regulate broader biological processes such as lipid metabolism and hematopoiesis, which can be linked to cardiovascular risks and blood disorders when disrupted.14-15,30 Highly selective allosteric inhibition of TYK2, with minimal inhibition of JAK1, 2 and 3, is a promising therapeutic approach to target immune-mediated inflammation while potentially avoiding risks associated with inhibition of other members of the JAK family.19

About Takeda
Takeda is focused on creating better health for people and a brighter future for
=*=*=*=*=*=
当前为第7/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页